Bio

Mark co-founded Torreya Partners with Tim Opler and has a long history of serving clients in the biotechnology industry. At Torreya, he leads our Biotech Advisory team and was recently involved in Compugen's $500mm+ oncology immunotherapy partnership with Bayer (2013). Mark continues to be highly active in advising a number of scientifically-oriented biotechnology companies, typically making recommendations that involve a long-term, scientifically oriented perspective. Mark has 30 years of experience advising life sciences companies and has worked on over 175 financing, licensing, and M&A transactions with a value in excess of $50 billion. Before co-founding Torreya, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup where he was involved with a team of 100 professionals. In his role, Mark was also involved in expanding Citigroup's global life sciences coverage in Europe and Japan. Before joining Citigroup, Mark spent a decade of his career at Robertson Stephens. He most recently a Managing Director at in both San Francisco and New York, where he mainly covered biotech sector and raised 45% of all biotech dollars and managed or co-managed 20% of all transactions from 1999 to 2001, making the Life Sciences franchise the No.1 revenue producer among the 7 industry groups at the firm. Notable IPOs Mark either led or worked on include Abgenix, Affymetrix, Alkermes, Alnylam, Cor Therapeutics, Esperion, Genentech, Genzyme, Gilead, Given Imaging, Imclone, Medicines, Millennium, Neurocrine, Progenics, and Rigel. Some of the secondary offerings or convertible transactions Mark also played an active role include Allergan, Amgen, Bone Care International, Centocor, Cephalon, Chiron, Cubist, Dov, Endo, Human Genome Sciences, ICOS, Immunex, Martek, NPS, OSI, Pain Therapeutics, Protein Design Labs, Regeneron, Schering-Plough, and Wyeth. Before moving into to Investment Banking, Mark was a senior research analyst covering biotech industry at the firm where he was a Wall Street All-Star Analyst three years in a row. Mark began his career as a research associate at Kidder Peabody in New York covering biotech and healthcare services industries. Mark holds a BA from Columbia College and a MBA from Harvard Business School. Mark is a registered representative with Financial West Group.